Gilead and Nucleai probe why target-positive tumors can still resist ADCs
recent articles
Creative Bioarray announced the release of its comprehensive biospecimens to satisfy diverse biological research needs. New York, USA – May 2, 2022 – Histobiolab, the mature division of Creative Bioarray, developing a well-equipped...
A new way of using artificial intelligence to predict cancer from patient data without putting personal information at risk has been developed. Artificial intelligence (AI) can analyse large amounts of data, such as images or trial...
PathPresenter: Pilot installation at The Ohio State University integrates ClinPx into Epic’s Beaker Laboratory Information System (LIS), allowing The Ohio State University (OSU) pathologists to receive, view, and sign out cases – uploaded...
Earlier this week Aiforia Technologies launched the Aiforia Community Platform — one of the only available platforms of this nature, for pathologists and scientists utilizing AI for image analysis software in preclinical and clinical...
THE TRIBUN EXECUTIVE TEAM IS EXPANDING WITH THE CREATION OF A VP PHARMA POSITION TO DEVELOP THE EXPANDING PHARMACEUTICAL BUSINESS. Paris, France, April 26th, 2022 - Tribun Health (Formerly Tribvn Healthcare) is pleased to announce...
PathPresenter Welcomes Patrick Myles as CEO Montville, NJ and Waterloo, ON | April 26, 2022, 10:00 AM, Eastern PathPresenter, the most widely used digital pathology workflow platform with 40,000 users in 172 countries, today announced the...
